From anxiety to chronic pain and easing the effects of chemotherapy, cannabinoid treatments are shaking off the negative stigma and gaining popularity all around the world.
In 2016, the Australian Government created a pathway for patients to access medicinal cannabis. However, while 29 conditions have been approved for cannabinoid treatment in Australia, it’s largely been a tricky, costly process with very few patients able to access and afford medicinal cannabis.
Dispensed—a new Australian portal to access medicinal cannabis—has arrived to change all that. Dispensed is Australia's first subscription-based online platform linking patients to cannabinoid treatments.
If you’re keen to explore cannabinoids, you can set up an account and be connected to an authorised prescriber for a free telehealth consult. From there, a doctor will determine your eligibility and design a tailored treatment plan based on your needs. Medicines are then sent directly to your door.
As well as being easy to access, Dispensed has no sign-up fees or hidden costs. "All of our services are included within a treatment plan, clinician consultations, and plant-based medicine," says Head of the Dispensed medical team, Adam Younes.
“It takes under five minutes to sign up. And once you have had your initial telehealth appointment you can find out whether plant-based medicine may be appropriate for you," Younes continues.
"If you are approved as a patient, medicine delivery is rapid and you can start treatment quickly. We hope these benefits help to make these medicines more accessible to Australians in need and who have exhausted traditional treatment options.”
Image credit: Dispensed
Editor's Note: The information in this article is provided for education and awareness only. It is not a substitute for professional health advice.
Urban List editors independently select and write about stuff we love and think you'll like too. Urban List has affiliate partnerships, and if you purchase something through the links in this article, we will earn a commission from those partners. To find out more about who we work with and why read our editorial policy here.